Clinical Trials Logo
  1. Home
  2. Urothelial Carcinoma Bladder
  3. NCT04740866

Adjuvant Radiotherapy Versus Observation After Radical Cystectomy in High Risk Urothelial Bladder Cancer

Urothelial Carcinoma Bladder Clinical Trial

Official title:
Prospective Randomized Trial of Adjuvant Radiotherapy Versus Observation After Radical Cystectomy in High Risk Urothelial Bladder Cancer

Clinical Trial Summary

This is a prospective randomized clinical trial in high risk urothelial bladder cancer to compare adjuvant radiotherapy versus observation after radical cyctectomy. This is to clarify the benefit of adjuvant radiotherapy while limiting gastrointestinal toxicities for patients with pathological high-risk bladder cancer through assessing locoregional control (LRC).

Clinical Trial Description

This is prospective randomized trial in high risk urothelial bladder cancer that includes 2 arms. The randomization will be done by permuted block method to 2 equal comparable groups. The total number of subjects will be 50 in each arm (Total=100 subjects). This study include patients who may receive neoadjuvant chemotherapy [Gemcitabine+Cisplatin]) or not. Arm (1) in this study (N=50) will received irradiation of both the bladder tumor bed and pelvic lymph nodes using IMRT technique. For Arm (2) (N=50) will undergo observation following radical cystectomy. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04740866
Study type Interventional
Source Cairo University
Contact Mohamed Zaghloul, MD
Phone (20)-01001720664
Email mszagh@yahoo.com
Status Recruiting
Phase N/A
Start date August 1, 2018
Completion date December 1, 2022
View Details
See also
  Status Clinical Trial Phase
Terminated NCT03606174 - A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma Phase 2
Recruiting NCT05839119 - Targeting Androgen Signaling in Urothelial Cell Carcinoma - Neoadjuvant Phase 1
Completed NCT03558503 - A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer Phase 2
Completed NCT05136898 - Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC) Phase 3
Withdrawn NCT06090318 - Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss Phase 1/Phase 2
Recruiting NCT03185468 - Intervention of Bladder Cancer by CAR-T Phase 1/Phase 2
Active, not recruiting NCT05243550 - A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer Phase 3
Recruiting NCT05312671 - Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer Phase 2
Recruiting NCT02951325 - Bladder Cancer Adjuvant Radiotherapy Trial N/A
Recruiting NCT05401279 - Bladder Sparing Treatment of Tislelizumab, Gemcitabine and Cisplatin for Patients With PD-L1 Positive Muscle Invasive Bladder Cancer Phase 2
Recruiting NCT05375903 - A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) Phase 1
Active, not recruiting NCT04386746 - Intravesical Gemcitabine and Docetaxel for BCG naïve Non-muscle Invasive Bladder Cancer Phase 2
Recruiting NCT06184516 - Assessment of Decision Tool to Select Women for Gynecologic Sparing Radical Cystectomy Phase 2
Not yet recruiting NCT05656235 - Renal Retention in High Grade Upper Tract Urothelial Cancer Phase 2
Not yet recruiting NCT06331299 - A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer Phase 3
Not yet recruiting NCT05037279 - Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC) Phase 3
Terminated NCT04688931 - A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer Phase 3
Recruiting NCT05241340 - Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer Phase 2
Recruiting NCT05077709 - IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC Phase 2
Completed NCT04200963 - A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma Phase 1